Akut koroner sendrom hastalarında koroner arter hastalığı ciddiyeti ile serum MFG-E8 düzeyleri arasındaki ilişki

Abstract

Amaç: MFG-E8 (süt yağı globül-epidermal büyüme faktörü 8, laktaderin olarak da bilinir) ateroskleroz, anjiyogenez, iskemi/reperfüzyon hasarı ve kanserler gibi birçok olumsuz klinik durumda önemli rol oynamaktadır. Bu çalışmada, akut koroner sendrom (ACS) hastalarında başvuru sırasında serum MFG-E8 düzeyinin koroner arter hastalığı (CAD) ciddiyeti ile ilişkisini araştırmayı amaçladık. Gereç ve Yöntem: Çalışmaya toplam 88 NSTEMI hastası alındı. Hastalar SYNTAX skorlama sistemine göre düşük SYNTAX skoru olanlar <23 (n=75) ve yüksek SYNTAX skoru olanlar ≥23 (n=13) olarak iki gruba ayrıldı. Bulgular: Korelasyon analizinde, MFG-E8 ile SYNTAX skoru arasında ilişki saptanmadı (r = 0.029, p>0.05). Ancak, MFG-E8 ve TIMI risk skoru arasında orta derece negatif korelasyon saptandı (r = -0.365, p = 0.001). Ek olarak, MFG-E8’in serum ürik asit düzeyi ile hafif negatif ilişkisi vardı (r = -0.232, p = 0.03). Ayrıca SYNTAX skoru yüksek olan grupta diyabetes mellitus (p = 0.031), monosit/HDL oranı (p = 0.049), TIMI risk skoru (p = 0.004) ve SYNTAX II (p = 0.012) skoru daha yüksek saptanırken, LVEF anlamlı olarak daha düşüktü (p = 0.014). Sonuç: NSTEMI hastalarında MFG-E8 düzeyleri, daha kötü klinik kardiyovasküler olay riski ve koroner arter hastalığı ciddiyeti göstergesi olan SYNTAX skoru ile ilişkili değildir. Ancak, NSTEMI ile başvuran hastalarda en sık kullanılan risk sınıflandırma modellerinden biri olan TIMI risk skoru ile serum MFG-E8 seviyeleri arasında negatif ilişki bulunmaktadır.

Keywords

• Miyokard enfarktüsü
• SYNTAX skoru
• İnflamasyon
• MFG-E8
• Akut koroner sendrom
• TIMI risk skoru

Association between serum MFG-E8 levels and coronary severity index in patients with acute coronary syndrome

Abstract

Aim: MFG-E8 (milk fat globule-epidermal growth factor 8, also known as lactaderin) plays an important role in many adverse clinical conditions such as atherosclerosis, angiogenesis, ischemia/reperfusion injury and cancers. The present study aims to investigate the association of serum MFG-E8 levels at admission with the severity of coronary artery disease (CAD) in patients with acute coronary syndrome (ACS). Material and Methods: A total of 88 patients were enrolled into the study. Patients were divided into two groups according to SYNTAX score as low SYNTAX score <23 (n=75) and high SYNTAX score ≥23 (n=13). Results: In correlation analysis, there was no statistically significant correlation between serum MFG-E8 levels and SYNTAX score (r = 0.029; p>0.05). However, there was a moderate and negative correlation between MFG-E8 levels and Thrombolysis In Myocardial Infarction (TIMI) risk score (r = -0.365, p = 0.001). A slightly negative association between serum uric acid level and MFG-E8 was also determined ( r = -0.232, p = 0.03). In addition, diabetes mellitus (p = 0.031), monocyte to HDL ratio (p = 0.049), TIMI risk score (p = 0.004) and SYNTAX II (p = 0.012) score were significantly higher in the high SYNTAX group with a significantly lower LVEF (p = 0.014). Conclusion: The serum levels of MFG-E8 were not found to be correlated with the SYNTAX score, an indicator of worsening clinical cardiovascular event risk and the severity of coronary artery stenosis. However, MFG-E8 levels were found to be correlated with TIMI risk score, which is one of the most commonly used risk stratification model for patients presenting with non-ST segment elevation miyocardial infarction (NSTEMI).

Keywords

• Myocardial infarction
• SYNTAX score
• Inflammation
• MFG-E8
• Acute coronary syndrome
• TIMI risk score

References

1. 1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006; 367(9524):1747-1757.
2. 2. Ertas F, Can Ö, Acet H, Ozbakkaloglu M. The clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study. Postepy Kardiol Interwencyjnej. 2013;9(4):328-331.
3. 3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-1143.
4. 4. Pearson TA, Mensah GA, Alexander RW, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation. 2003;107(3): 499-511.
5. 5. Montero-Vega MT. The inflammatory process underlying atherosclerosis. Crit Rev Immunol 2012;32(5):373e462.
6. 6. Manduteanu I, Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med 2012;16(9):1978e90.
7. 7. Akakura S, Singh S, Spataro M, et al. The opsonin MFG-E8 is a ligand for the alphavbeta5 integrin and triggers DOCK180-dependent Rac1 activation for the phagocytosis of apoptotic cells. Exp Cell Res. 2004;292(2):403–416.
8. 8. Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. Identification of a factor that links apoptotic cells to phagocytes. Nature. 2002;417(6885):182–187.

9. 9. Li BZ, Zhang HY, Pan HF, Ye DQ. Identification of MFG-E8 as a novel therapeutic target for diseases. Expert Opin Ther Targets. 2013; 17:1275–1285.
10. 10. Henson PM, Bratton DL, Fadok VA. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol. 2001;2:627– 633.
11. 11. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965–975.
12. 12. Silvestre JS, Thery C, Hamard G, et al. Lactadherin promotes VEGF-dependent neovascularization. Nat Med. 2005; 11:499– 506.
13. 13. Collet JP, Thiele H, Barbato E, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-1367.
14. 14. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228.
15. 15. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013 May 23;368(21):2004-13.
16. 16. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653-657.
17. 17. Aziz M, Jacob A, Matsuda A, Wang P. Review: milk fat globule-EGF factor 8 expression, function and plausible signal transduction in resolving inflammation. Apoptosis 2011;16(11):1077e86.
18. 18. Aziz MM, Ishihara S, Mishima Y, et al. MFG-E8 attenuates intestinal inflammation in murine experimental colitis by modulating osteopontin-dependent alphavbeta3 integrin signaling. J Immunol 2009;182(11):7222e32.
19. 19. Matsuda A, Jacob A, Wu R, et al. Milk fat globule-EGF factor VIII in sepsis and ischemia-reperfusion injury. Mol Med 2011;17(1e2):126e33.
20. 20. Komura H, Miksa M, Wu R, Goyert SM, Wang P. Milk fat globule epidermal growth factor-factor VIII is down-regulated in sepsis via the lipopolysaccharide-CD14 pathway. J Immunol 2009;182(1):581e7.
21. 21. Bu HF, Zuo XL, Wang X, et al. Milk fat globule-EGF factor 8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium. J Clin Invest 2007;117(12):3673e83.
22. 22. Boddaert J, Kinugawa K, Lambert JC, et al. Evidence of a role for lactadherin in Alzheimer’s disease. Am J Pathol 2007;170(3):921e9.
23. 23. Yamaguchi H, Takagi J, Miyamae T, et al. Milk fat globule EGF factor 8 in the serum of human patients of systemic lupus erythematosus. J Leukoc Biol 2008;83(5):1300e7.
24. 24. Watanabe T, Totsuka R, Miyatani S, et al. Production of the long and short forms of MFG-E8 by epidermal keratinocytes. Cell Tissue Res 2005;321(2): 185e93.
25. 25. Ait-Oufella H, Kinugawa K, Zoll J, et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation 2007;115(16):2168e77.
26. 26. Dai W, Li Y, Lv YN, Wei CD, Zheng HY. The roles of a novel anti-inflammatory factor, milk fat globule-epidermal growth factor 8, in patients with coronary atherosclerotic heart disease. Atherosclerosis. 2014 Apr;233(2):661-665.
27. 27. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103(13):1813e8.
28. 28. Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 2008;79(Suppl. 8):15.
29. 29. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995;141(7):637-44.
30. 30. Ndrepepa G, Braun S, King L, Fusaro M, Tada T, Cassese S. Uric acid and prognosis in angiography-proven coronary artery disease. Eur J Clin Invest 2013;43(3):256-66.
31. 31. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 2005;96(4):489-95.
32. 32. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997 Aug 7;337(6):408-16. 33. Rao SS, Agasthi P. Thrombolysis In Myocardial Infarction Risk Score. 2021 Feb 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.